Article

Acute intravenous injection toxicity of BMEDA in mice.

Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan.
Drug and Chemical Toxicology (impact factor: 1.08). 01/2011; 34(1):20-4. DOI:10.3109/01480545.2010.482588 pp.20-4
Source: PubMed

ABSTRACT (188)Re/(186)Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine-labeled pegylated liposome ((188)Re-BMEDA-liposome) has been proven as a promising candidate for cancer therapy in tumor-rodent models. (188)Re-BMEDA complexes should be prepared for the radiolabeling of liposomes. This article describes the acute toxicity of BMEDA in Imprinting Control Region (ICR) mice. Treated mice were administered with BMEDA at dose levels of 3, 6, 9, and 12 mg/kg, with a dose volume of 10 mL/kg. The control mice were administered 10 mL/kg of vehicle control. The mice were observed for 14 days. Observations included mortality, clinical signs, total body-weight gains, food consumption, and gross necropsy findings. BMEDA exerted no adverse toxic effects in ICR mice at dose levels 3 mg/kg, which are up to 360,000 times higher than the intended human dose. The lethal-dose (LD(50)) value of BMEDA was 8.13 and 8.68 mg/kg in male and female mice, respectively.

0 0
 · 
0 Bookmarks
 · 
45 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

acute toxicity
 
adverse toxic effects
 
clinical signs
 
control mice
 
dose levels
 
dose levels 3 mg/kg
 
dose volume
 
female mice
 
gross necropsy findings
 
ICR
 
ICR mice
 
Imprinting Control Region
 
intended human dose
 
lethal-dose
 
Observations
 
promising candidate
 
radiolabeling
 
total body-weight gains
 
tumor-rodent models
 
vehicle control